Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.

Linsenmeier L, Mohammadi B, Shafiq M, Frontzek K, Bär J, Shrivastava AN, Damme M, Song F, Schwarz A, Da Vela S, Massignan T, Jung S, Correia A, Schmitz M, Puig B, Hornemann S, Zerr I, Tatzelt J, Biasini E, Saftig P, Schweizer M, Svergun D, Amin L, Mazzola F, Varani L, Thapa S, Gilch S, Schätzl H, Harris DA, Triller A, Mikhaylova M, Aguzzi A, Altmeppen HC, Glatzel M
Sci Adv 7(48):eabj1826 (2021 Nov 26)
PMID: 34818048
doi: 10.1126/sciadv.abj1826 		Submitted to SASBDB: 2021 Mar 29
Published in SASBDB:

SASDLT2 – 6D11 IgG monoclonal antibody

Anti-prion protein monoclonal IgG2a 6D11 experimental SAS data
CORAL model
Sample: Anti-prion protein monoclonal IgG2a 6D11 monomer, 145 kDa Mus musculus protein
Buffer: phosphate buffered saline, pH: 7.4
Experiment: SAXS data collected at EMBL P12, PETRA III on 2019 Dec 15
RgGuinier 5.1 nm
Dmax 17.4 nm
VolumePorod 330 nm3

SASDLU2 – 2:1 complex between anti prion protein monoclonal IgG 6D11 and recombinant murine prion protein

Major prion proteinAnti-prion protein monoclonal IgG2a 6D11 experimental SAS data
OTHER model
Sample: Major prion protein monomer, 23 kDa Mus musculus protein
Anti-prion protein monoclonal IgG2a 6D11 monomer, 145 kDa Mus musculus protein
Buffer: phosphate buffered saline, pH: 7.4
Experiment: SAXS data collected at EMBL P12, PETRA III on 2019 Dec 15
RgGuinier 8.1 nm
Dmax 24.8 nm
VolumePorod 710 nm3